NRXS Stock — NeurAxis, Inc.

NeurAxis, Inc. (NRXS)

Updated October 16, 2026.

NRXS is a Stock. Total return is 28.3% over the past 3.2 years, 49.9 points behind SPY at 78.2%.

NeurAxis, Inc. is a medical technology company developing neuromodulation therapies for chronic conditions, with a focus on electrical nerve stimulation systems for gastrointestinal disorders in children and adults. The company does not currently have an established distribution pattern. This early-stage healthcare company may appeal to growth-oriented investors seeking exposure to medical device innovation, though it carries the risks typical of developing-stage medical technology businesses.

NRXS performance versus SPY

Price and return data through 2026-10-16.

Total return is 28.3% over the past 3.2 years, 49.9 points behind SPY at 78.2%. Over the past year its total return — price change plus distributions reinvested — is 145.2%. Its deepest 1-year drawdown was 39.5%.

NRXS key facts

Asset type

Stock

Asset class

Equity

Inception date

08/09/2023

Distribution frequency

None

Last close

$7.70 (as of 2026-10-16)

Market cap

$96,694,790

Average volume

229212.0

Beta

1.365

Payout ratio

0.0%

EPS

$-0.78

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

NRXS risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 39.5%.

Who may consider NRXS — and who may not

It is a weaker fit for investors who need monthly cash flow (NRXS does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on NRXS

• All tickers starting with N

Tagged: Healthcare.

Frequently asked questions